Ideas
How promising science becomes an evidence-backed product or venture that survives contact with clinical practice, regulation, markets and scale.
Geographic perspectives within this idea territory.
A curated route into the central arguments, rather than a chronological dump.
Published on linkedin on June 17th 1. Not enough evidence! When we first embarked on developing Hepatopredict, our idea was very clear: create a biomarker-based test that could reliably inform clinical decisions about liver transplantation in patients with hepatocellular carcinoma (HCC). In our minds, the pathway was straightforward: demonstrate a strong correlation with clinical outcomes,…
Read →Published on LinkedIn on Nov 20th In Part 1/2 (https://www.linkedin.com/pulse/rebuilding-case-diagnostics-investment-12-reflections-pereira-leal-swvbf), I discussed why diagnostics face a systematic funding gap despite being essential infrastructure for precision medicine, and outlined five strategic directions for entrepreneurs building diagnostic companies. Those reflections emerged from building Ophiomics and follow from the reflection I’ve been making for my book, Precision Diagnostics:…
Read →Presenting at the Ciência 2010, a national science showcasing initiative by FCT and other governmental agencies, about “TRANSLATING BIOINFORMATICS RESEARCH FOR HEALTH, BIOTECH AND THE ECONOMY“, at the Bioinformatics and Computational Biology session.
Read →Opinion published (in Portuguese) on the national newspaper Diário de Notícias where I defend the need for a scale up strategy for Portuga. A consistent, bi-partisan effort to support entrepreneurship is steadily resulting in an abundance of start ups; now we need to help them go global: Venha daí uma estratégia de ‘Scale up’ para…
Read →